KENILWORTH, N.J. — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA, Merck’s anti-PD-1… Read More
The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models Approval moves NervGen one step closer… Read More
Investment will accelerate the overall Sarclisa® development program Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa® (isatuximab) PARIS — Sanofi and Blackstone (NYSE:… Read More
VANCOUVER, B.C. – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate… Read More
Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases NEW YORK — Pfizer Inc. (NYSE: PFE) announced today the… Read More
